ITCI
Intra-Cellular Therapies, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth +13.3% ·
share flow +7.6% ·
net new positions +11.8%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q1 2025 | 17 | +2 | 13.58M | $1.79B | +3 | −1 |
| Q4 2024 | 15 | +1 | 12.62M | $1.05B | +1 | — |
| Q3 2024 | 13 | -1 | 9.99M | $731.14M | +1 | −2 |
| Q2 2024 | 14 | — | 9.81M | $671.63M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Norges Bank ✦ (passive) | 3.58M | +11.4% | $472.22M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 2.24M | +1795.5% | $295.12M | 0.3% | ▲ Add | 2 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 2.24M | +1795.5% | $295.12M | 0.3% | ▲ Add | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.83M | +6.7% | $241.74M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.83M | +6.7% | $241.74M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | State Street Global Advisors ✦ (passive) | 1.78M | -5.0% | $234.99M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 923.81K | +72.8% | $121.87M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 923.81K | +72.8% | $121.87M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 9 | Millennium Management ✦ | 844.07K | +62.1% | $111.35M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 621.20K | +97.5% | $81.95M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 11 | Marshall Wace ✦ | 440.67K | -59.2% | $58.13M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 12 | Marshall Wace ✦ | 440.67K | -59.2% | $58.13M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 13 | Marshall Wace ✦ | 440.67K | -59.2% | $58.13M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 14 | Adage Capital Partners ✦ | 298.39K | -56.0% | $39.36M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 266.33K | -50.4% | $35.13M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 266.33K | -50.4% | $35.13M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 266.33K | -50.4% | $35.13M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 266.33K | -50.4% | $35.13M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 266.33K | -50.4% | $35.13M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 193.89K | +35.8% | $25.58M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 21 | Wellington Management ✦ | 190.37K | -81.6% | $25.11M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 22 | Wellington Management ✦ | 190.37K | -81.6% | $25.11M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 23 | Wellington Management ✦ | 190.37K | -81.6% | $25.11M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 24 | Wellington Management ✦ | 190.37K | -81.6% | $25.11M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 25 | Soros Fund Management ✦ | 116.59K | New | $15.38M | 0.4% | New | 1 | SEC ↗ |
| 26 | T. Rowe Price ✦ | 115.42K | -80.4% | $15.23M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 27 | T. Rowe Price ✦ | 115.42K | -80.4% | $15.23M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 28 | Arrowstreet Capital ✦ | 79.29K | New | $10.46M | 0.0% | New | 1 | SEC ↗ |
| 29 | GAMCO Investors ✦ | 38.10K | New | $5.03M | 0.1% | New | 1 | SEC ↗ |
| 30 | Gotham Asset Management ✦ | 18.51K | +68.2% | $2.44M | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Soros Fund Management | $15.38M | 0.4% |
| Arrowstreet Capital | $10.46M | 0.0% |
| GAMCO Investors | $5.03M | 0.1% |
Exited
| Point72 Asset Management | $21.03M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 1 shares, $2,540 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.